In vitro and in vivo effects of fulvestrant combined with trastuzumab in breast cancer with estrogen receptor-positive and HER-2/neu-overexpressing

被引：0
|
作者：
Chen, Q. [1 ]
Wu, K. [1 ]
Lu, Y. [1 ]
Ding, L. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Gen Surg, Shanghai 200030, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页码：S121 / S122
页数：2
相关论文
共 50 条
  • [21] HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer
    Dowsett, M
    Harper-Wynne, C
    Boeddinghaus, I
    Salter, J
    Hills, M
    Dixon, M
    Ebbs, S
    Gui, G
    Sacks, N
    Smith, I
    CANCER RESEARCH, 2001, 61 (23) : 8452 - 8458
  • [22] TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
    Eralp, Yesim
    JOURNAL OF BREAST HEALTH, 2009, 5 (01): : 3 - 8
  • [23] SUPPRESSED TRANSFORMATION AND INDUCED-DIFFERENTIATION OF HER-2 NEU-OVEREXPRESSING BREAST-CANCER CELLS BY EMODIN
    ZHANG, LS
    CHANG, CJ
    BACUS, SS
    HUNG, MC
    CANCER RESEARCH, 1995, 55 (17) : 3890 - 3896
  • [24] Inhibition of cell growth by BrMC through inactivation of Akt in HER-2/neu-overexpressing breast cancer cells
    Cao, Xiao-Zheng
    Xiang, Hong-Lin
    Quan, Mei-Fang
    He, Li-Hua
    ONCOLOGY LETTERS, 2014, 7 (05) : 1632 - 1638
  • [25] HER-2/neu positive breast cancer:: how to prescribe adjuvant trastuzumab (Herceptin®)?
    Belkacemi, Yazid
    Gligorov, Joseph
    Mauriac, Louis
    Azria, David
    BULLETIN DU CANCER, 2006, 93 (10) : 991 - 999
  • [26] Proteomic characterization of Her2/neu-overexpressing breast cancer cells
    Chen, Hexin
    Pimienta, Genaro
    Gu, Yiben
    Sun, Xu
    Hu, Jianjun
    Kim, Min-Sik
    Chaerkady, Raghothama
    Gucek, Marjan
    Cole, Robert N.
    Sukumar, Saraswati
    Pandey, Akhilesh
    PROTEOMICS CLINICAL APPLICATIONS, 2011, 5 (3-4) : 201 - 201
  • [27] Activity of fulvestrant in a subset of estrogen receptor-positive patients with advanced breast cancer that overexpresses HER-2.
    Robertson, J. F. R.
    Agrawal, A.
    Paish, C.
    Cheung, K. L.
    Ellis, I. O.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S194 - S195
  • [28] ELUCIDATING THE EFFECTS OF β-OESTRADIOL, CALCIPOTRIOL OR CONCURRENT TRASTUZUMAB IN HER-2 OVEREXPRESSING AND OESTROGEN RECEPTOR POSITIVE BREAST CANCERS
    Outhoff, K.
    Hurrell, T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 307 - 307
  • [29] Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
    Van Asten, Kathleen
    Slembrouck, Laurence
    Olbrecht, Siel
    Jongen, Lynn
    Brouckaert, Olivier
    Wildiers, Hans
    Floris, Giuseppe
    Van Limbergen, Erik
    Weltens, Caroline
    Smeets, Ann
    Paridaens, Robert
    Giobbie-Hurder, Anita
    Regan, Meredith M.
    Viale, Giuseppe
    Thurlimann, Beat
    Vergote, Ignace
    Christodoulou, Evangelia
    Van Calster, Ben
    Neven, Patrick
    ONCOLOGIST, 2019, 24 (02): : 165 - 171
  • [30] Enhanced adenoviral transduction efficiency in HER-2/neu-overexpressing human breast cancer cells not induced by an integrin pathway
    Kim, JS
    Jeon, HM
    Im, SA
    Lee, SN
    Kim, JS
    ONCOLOGY REPORTS, 1999, 6 (06) : 1237 - 1242
12345